What's Happening?
Vietnam Vaccine Joint Stock Company (VNVC) and French pharmaceutical company Sanofi are advancing their partnership to enhance Vietnam's domestic vaccine manufacturing capabilities. This collaboration was highlighted during the Vietnam-France High-Level
Conference in Hanoi, focusing on strategic technologies and next-generation vaccine development. The partnership aims to boost Vietnam's self-sufficiency in vaccine production, a strategic priority for the country following the COVID-19 pandemic. Sanofi, with over a century of vaccine manufacturing experience, is committed to sharing its technological expertise with VNVC to develop high-quality vaccine manufacturing capabilities in Vietnam.
Why It's Important?
This partnership is significant as it aims to strengthen Vietnam's healthcare system by ensuring a stable vaccine supply and supporting the country's ambition to become a regional hub for vaccine manufacturing. By enhancing domestic production capabilities, Vietnam can reduce its reliance on imported vaccines, improve public health security, and support long-term economic growth. The collaboration also reflects a broader trend of countries seeking to bolster their healthcare infrastructure and resilience in response to global health challenges.
What's Next?
VNVC and Sanofi plan to continue their collaboration by investing in research, technology transfer, and workforce development. The VNVC Vaccine and Biological Manufacturing Plant, with an initial investment of over $95 million, is expected to begin operations by the end of 2027. The first vaccine batches produced in Vietnam are anticipated to be available by 2028, marking a significant step towards achieving vaccine self-sufficiency and reducing vaccination costs for the Vietnamese population.
